Anti-tumor immune responses are stifled by the C5a-driven recruitment of myeloid-derived suppressor cells, which support tumorigenesis by upregulating anti-inflammatory (inhibitory) molecules such as Programmed Death-Ligand 1 (PD-L1), transforming growth factor-β (TGF-β) and IL-10 (62–64). The gene discussed is TGFB1; the disease is neoplasm.